60 Degrees Pharmaceuticals filings document a specialty pharmaceutical issuer with Nasdaq-listed common stock and warrants, emerging-growth-company status and a business focused on medicines for vector-borne disease. Its recent Form 8-K disclosures record material events involving the company’s at-the-market equity offering program, related legal opinions, beneficial-ownership corrections, investor-presentation materials, and clinical development and regulatory strategy updates.
The filing record also covers capital-structure and governance matters, including a one-for-four reverse stock split approved through amendments to the certificate of incorporation, annual meeting voting results and Nasdaq listing-compliance notices. These disclosures frame the company’s formal reporting around ARAKODA, tafenoquine development, equity financing mechanics, security-holder votes and exchange-related requirements.
60 Degrees Pharmaceuticals, Inc. (SXTP) said Nasdaq staff determined to delist its securities after their bid price closed below $1.00 per share for 30 consecutive business days, from October 8 through November 18, 2026. Nasdaq said the company’s reverse splits in February 2025 and January 2026, with a cumulative 1-for-20 ratio, made it ineligible for a compliance period under the applicable rule.
The company has requested a Hearings Panel hearing and paid a $20,000 fee; the hearing request stays suspension and the Form 25-NSE filing pending the Panel’s decision. Continued listing is not assured.
The company expects its reverse split to take effect on December 2, 2026, with split-adjusted trading expected that day. It says the split is intended to increase the bid price and regain compliance, but does not assure the split will occur or achieve that result.
60 Degrees Pharmaceuticals (SXTP) reported third-quarter 2026 net product revenue of $233,235, compared with $437,602 a year earlier, and a net loss attributable to common stockholders of $2,681,383, versus $2,444,421. For the nine months ended September 30, 2026, net product revenue was $603,225 versus $702,086 and common-stockholder loss was $7,294,268 versus $6,299,559. Nine-month operating cash use was $6,419,897, while cash and cash equivalents were $306,191 as of September 30, 2026.
Management estimated that cash and expected product revenues would fund operations only through early December 2026, taking into account $471,329 received at closing of the November 2026 warrant inducement, net of placement agent fees and before $75,000 of related legal costs. The estimate assumes payment deferrals and continued vendor accommodations; management said its plans do not alleviate substantial doubt about the company’s ability to continue as a going concern for at least one year after the financial statements were issued. As of September 30, 2026, declining stock price left no available capacity to sell additional shares under the ATM agreement under Form S-3’s limit of one-third of public float in any 12-month period.
60 Degrees Pharmaceuticals, Inc. (SXTP) is the issuer whose shares CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc., report in Amendment No. 3 to Schedule 13G. Each reports beneficial ownership of 197,911 shares, consisting of shares issuable upon warrant exercise; the identical reported figures are not additive. The reported amount represents 5.3% of the class.
Heights Capital Management may exercise shared voting and dispositive power over the shares for CVI. The warrants cannot be exercised to the extent aggregate beneficial ownership would exceed 9.99%. The issuer reported 3,516,988 shares outstanding as of August 14, 2026. Both reporting persons disclaim beneficial ownership except for their pecuniary interest.
60 Degrees Pharmaceuticals, Inc. was the issuer in an ownership report by Orca Capital AG, which reported beneficial ownership of 222,934 shares of common stock, or 5.6% of the class. Orca's percentage calculation used 4,002,796 common shares and excluded 445,868 shares issuable upon exercise of warrants. The warrants are subject to a 4.99% blocker, which prevents exercise to the extent it would result in Orca beneficially owning more than 4.99% of the outstanding common stock.
60 Degrees Pharmaceuticals, Inc. (SXTP) is the issuer in an amended beneficial-ownership report stating that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC each may have been deemed to beneficially own 390,342 shares, reported as 9.99%, as of September 30, 2026. The amount consists of 131,579 shares issuable under each of Intracoastal Warrants 1 and 2 and 127,184 shares issuable under Warrant 3. The reporting persons reported shared voting and dispositive power over 390,342 shares and zero sole power.
The percentage calculation uses 3,516,988 shares outstanding as of August 14, 2026, plus the shares issuable under the three warrants. Blocker provisions exclude additional warrant shares when exercise would cause beneficial ownership to exceed limits of 9.99% or 4.99%, depending on the warrant. The report states that without those blockers, each reporting person may have been deemed to beneficially own 690,685 shares.
60 Degrees Pharmaceuticals, Inc. (SXTP) agreed with holders that they would exercise existing warrants for cash to acquire 584,492 shares at $0.90 per share, a reduced exercise price. The company expects $526,042.80 in gross proceeds before placement-agent fees and other offering expenses, for working capital and general corporate purposes. In exchange, it will issue unregistered new warrants for up to 1,168,984 shares, 200% of the shares issued on exercise. Closing is expected on or about November 9, 2026, subject to customary closing conditions.
The new warrants have a $0.90 exercise price and cannot be exercised before stockholder approval, which is not assured. Warrants for 560,912 shares expire five years after the later of the approval date or resale-registration effectiveness; warrants for 608,072 shares expire after 24 months from that later date. SXTP agreed to file a resale registration statement within 30 calendar days and seek approval at a stockholder meeting within 90 days. Placement-agent compensation includes fees of 7.5% and 1.0% of gross exercise proceeds, $10,000 in non-accountable expenses, and warrants for up to 43,837 shares.
60 Degrees Pharmaceuticals, Inc. (SXTP) reported results for the first five patients to complete tafenoquine-containing combination treatment in its expanded access study of relapsing babesiosis in immunosuppressed patients. All five reported being much or very much improved and had negative conventional PCR results during treatment or follow-up. Four of five (80%) had nonreactive post-treatment blood-donor NAT results; the fifth had a reactive NAT despite a negative follow-up conventional PCR. NAT samples were collected 66–120 days after treatment.
Two additional patients remain on treatment, bringing enrollment to seven; the study remains open pending potential FDA discussions. The company expects to unblind its separate randomized, placebo-controlled hospitalized-patient study in January 2027 and then intends to request a pre-sNDA meeting. It plans to pursue accelerated approval if its efficacy dossier is based primarily on data from immunosuppressed patients with relapsing babesiosis. Tafenoquine is not FDA-approved to treat or prevent babesiosis, and the company cautioned that the small uncontrolled study and historical case comparisons may not predict outcomes in larger studies.
60 Degrees Pharmaceuticals, Inc. updated its investor presentation on tafenoquine development for babesiosis, covering chronic, relapsing and severe acute programs. Tafenoquine is not approved by FDA or EMA for babesiosis; the presentation lists approved uses for malaria prevention and single-dose radical cure of P. vivax malaria with chloroquine.
The randomized hospital study enrolled 30 subjects, remains blinded, and has follow-up completion and unblinding planned for January 2027. Three expanded-access patients had post-treatment NAT-negative results; outcomes for two others were pending. In the chronic B-FREE screening, 2 of 9 patients were positive on genus-level dPCR; 0 of 9 were positive on B. microti NAT and 0 of 9 on Mayo species-specific PCR, and no enrolled patient had yet qualified for the primary per-protocol analysis. A pre-sNDA meeting was planned for late January 2027. The presentation describes a potential sNDA in 2027, with the lead regulatory path depending on the hospital-study result, and a September 2026 request for national-priority review.
The presentation identifies substantial doubt about the company's ability to continue as a going concern as a risk.
60 Degrees Pharmaceuticals (SXTP) has suspended further enrollment in its randomized severe-babesiosis study and intends to finalize the analysis with the 30 subjects enrolled as of October 1, 2026. It plans to unblind the study and report primary and secondary endpoint results in January 2027. The DSMB recommended completing the originally planned enrollment of 33 patients; the company cites marginal impact from three additional patients and seasonal enrollment that could delay unblinding by a year.
The DSMB analysis identified no safety issues, but did not establish whether the study met its endpoints. The company plans to request a pre-sNDA meeting with FDA in January 2027. It also reported molecular cure, using a sensitive NAT, in the first three patients in its expanded-access study; screening data for two additional patients are expected in early November 2026. Any accelerated-approval pathway is subject to FDA review. The company states substantial doubt about its ability to continue as a going concern.
60 DEGREES PHARMACEUTICALS, INC. (SXTP) reports that on September 12, 2026 it submitted a Statement of Interest to the FDA requesting a Commissioner’s National Priority Voucher for an efficacy supplement to NDA 210607 for ARAKODA (tafenoquine) to treat babesiosis, a tick-borne parasitic disease with no FDA-approved therapy. The company highlights published case reports in treatment‑refractory babesiosis showing cure rates of about 83% when tafenoquine is added to atovaquone-based therapy, and confirms that all three currently evaluable patients in its FDA‑authorized expanded access study have been cured.
The company is conducting a randomized, double‑blind, placebo‑controlled trial (NCT06207370), with enrollment for a prespecified interim analysis complete and a DSMB review scheduled for October 1, 2026. Depending on that outcome, it plans either regular approval based on the trial or accelerated approval supported by expanded‑access and published data, targeting an sNDA submission in March–April 2027. The company states that CNPV review could allow tafenoquine to become the first FDA‑approved babesiosis treatment by or before the 2027 tick season, and it commits to manufacture more than 50% of the value of any CNPV‑supported products in the U.S. and to provide volume‑based discounts to federal programs.